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REVIEWS 
Imbalance of Endothelium-derived Relaxing 
and Contracting Factors 
A New Concept in Hypertension? 
T. F. Luscher 
The endothelium has a strategical anatomical 
position between the circulating blood and vascular 
smooth muscle cells. It has recently been recog­
nized that endothelial cells play an important 
regulatory role in the circulation. The cells metabo­
lize or activate vasoactive hormones (ie, norepi­
nephrine, serotonin, bradykinin, angiotensin II), 
produce substances involved in coagulation and can 
release endothelium-derived relaxing factors and 
contracting factors. Nitric oxide and prostacyclin are 
vasodilators and inhibitors of platelet function. 
Endothelin is the most potent vasoconstrictor 
substance known. Thus, the endothelium can pro­
foundly affect platelet adhesion and aggregation, 
vascular smooth muscle tone and possibly also 
vascular smooth muscle growth. Under physiologi­
cal conditions, endothelium-derived relaxing 
factors appear to dominate. In contrast, in hyper­
tensive and atherosclerotic arteries the release of 
endothelium-derived relaxing factors and/or the 
responsiveness of vascular smooth muscle cells to 
the relaxing factors is reduced, while that of 
endothelium-derived contracting factors is aug­
mented. This imbalance of endothelium-derived re­
laxing and contracting factors may be important in 
the pathogenesis of hypertension and its cardiovas­
cular complications. Am J Hypertens 1990; 3:317-330 
K E Y W O R D S : Acetylcholine, angiotensin, 
atherosclerosis, endothelin, nitric oxide platelets, 
prostaglandins, vascular occlusion. 
The functional importance of endothelial cells as regulators of cardiovascular function has been increasingly recognized in the last decade. 1" 4 It has been known for years that endothelial cells 
play an important role in the regulation of movement of 
fluids from the blood to the tissue.5 The endothelium 
also plays a metabolic role by clearing the blood of hor-
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mones such as norepinephrine and serotonin. The con­
verting enzyme of the endothelial cell membrane trans­
forms angiotensin I into angiotensin II and inactivates 
the vasodilator bradykinin. 2 - 7 Further, endothelial cells 
can profoundly affect coagulation, platelet function and 
fibrinolysis.1'8-11 More recently, it has been recognized 
that endothelial cells produce vasoactive factors which 
can inhibit or activate vascular smooth muscle cells (Fig­
ure l ) 1 ' 2 ' 1 2 - 1 5 This article updates previous r e v i e w s 4 1 6 - 1 8 
and focuses on the possibility that endothelial cells act 
both as mediators and targets of hypertension and its 
complications. 
STRUCTURAL CHANGES OF THE 
ENDOTHELIUM IN HYPERTENSION 
In rat models of hypertension endothelial cells exhibit 
morphological changes. 4 , 1 9 " 2 3 Indeed, although the in­
tegrity of the endothelium is preserved, an increased 
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FIGURE 1. Endothelium-derived vasoactive substances. 
AA = Arachidonic acid; ACE = Angiotensin converting enzyme; 
ATG = Angiotensinogen; ACh = Acetylcholine; ATI/II = 
Angiotensin I/II; cAMP/cGMP = cyclic adenosine/guanosine 
monophosphate; EDCF = Endothelium-derived constricting fac­
tors); EDHF = Endothelium-derived hyperpolarizing factor; 
NO = Nitric oxide; PGI2 = Prostacyclin. Modified from Ref. 18. 
permeability, number, volume and replication rate of 
endothelial cells has been noted . 4 1 9 " 2 3 Transmission 
electronmicroscopy studies have shown that the num­
ber of cytoplasmatic organelles, such as the rough endo-
plasmatic reticulum, polyribosomes, microtubules, 
mitochondria and Golgi complexes, as well as the num­
ber of actin microfilament bundles and the length and 
complexity of tight junctions, is augmented in experi­
mental hypertension.2 0"2 2 Focal expansion of the suben-
dothelial space due to accumulation of granular matrix 
occurs early during the hypertensive process and be­
comes more pronounced as the disease progresses.2 1 , 2 3 
ENDOTHELIUM-DERIVED 
VASOACTIVE SUBSTANCES 
Endothelium-derived Relaxing Factors Furchgott 
and Zawadzki2 first demonstrated that the relaxation of 
isolated arteries induced by acetylcholine is endothe­
lium-dependent and mediated by the labile substance 
endothelium-derived relaxing factor (EDRF) (Figure 2). 
Hemoglobin, oxygen-derived free radicals and antioxi­
dants are effective inhibitors of E D R F . 2 4 " 2 8 The factor is 
a potent vasodilator and inhibitor of platelet adhesion 
and aggregation (Figure 3 ) . 2 , 8 , 9 , 2 9 In vascular smooth 
muscle cells and platelets EDRF stimulates soluble gua-
nylate cyclase and in turn increases the intracellular 
levels of cyclic guanosine 3',5'-monophosphate (cyclic 
GMP) (Figure l ) . 8 9 2 9 3 0 Substances interfering with the 
production of cyclic GMP (methylene blue, LY 83583) 
inhibit endothelium-dependent relaxations.3 , 4 , 2 4 The 
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FIGURE 2. Endothelium-dependent relaxation to acetylcholine 
in a human internal mammary artery (NE, norepinephrine; origi­
nal recording). The relaxation to acetylcholine (Ach) can be re­
versed by hemoglobin (Hb; 10r5 mol/L; upper panel). From Ref. 50, 
by permission. 
similarity of the actions of EDRF and nitrovasodilators 
indicated that endothelial cells might produce an en­
dogenous nitrate. Indeed, after independent proposals 
by Furchgott3 1 and Ignarro,3 2 Palmer, Ferrige and Mon-
cada demonstrated that endothelial cells in culture re­
lease nitric oxide in response to bradykinin.3 3 Nitric 
oxide has a similar half-life and mode of action as EDRF 
and the amounts released from endothelial cells in cul­
ture after stimulation with bradykinin appear sufficient 
to explain the biological activity of the factor in vascular 
tissues and in platelets. L-Arginine is the precursor sub­
stance from which nitric oxide is cleaved by specific 
enzymes. 3 4 , 3 5 EDRF is released in response to flow (ie, 
shear stress),3 6 3 7 platelet-derived products (ie, adeno­
sine diphosphate, thrombin, serotonin)3 8" 4 1 and certain 
hormones and autacoids (ie, bradykinin, histamine, 
noradrenalin, substance Ρ and vasopressin). 4 2 - 4 6 Aggre­
gating platelets release large amounts of adenine nu­
cleotides and serotonin which can evoke endothelium-
dependent relaxations in isolated blood vessels.3 9"4 1 
Adenosine diphosphate is the main mediator of the re­
sponse to aggregating platelets in human and canine 
coronary arteries,4 1 , 4 7 while in the pig serotonin is me­
diating the effect (Figure 3 ) . 4 8 Thrombin which is 
formed after activation of the coagulation cascade 
evokes potent endothelium-dependent relaxations also 
in human blood vessels. 4 9 , 5 0 In addition to EDRF, plate­
let-derived products and thrombin can also stimulate 
the endothelial production of prostacyclin (PGI2) and 
tissue plasminogen activator.1 0 Indeed, PGI 2 — a vaso­
dilator and inhibitor of platelet function which stimu­
lates cyclic adenosine 3^5'-monophosphate (cyclic 
AMP) 1 , 4 , 1 1 — and EDRF potentiate each other's vascular 
and antiaggregatory effects even at subthreshold con-
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FIGURE 3. Endothelium and 
platelet-vessel wall interaction. The 
production and release of endothe­
lium-derived relaxing factor (EDRF) 
and endothelin-1 can be stimulated 
by platelet-derived substances such 
as thrombin, and in the case of the 
former (in human arteries) also by 
adenosine tri- and diphosphate 
(ATP/ADP), histamine (EST), bra-
dykinin (Bk) and substance Ρ (SP). 
EDRF causes vascular relaxation 
and inhibition of platelet function 
(—), while endothelin-1 mainly 
causes profound contraction of 
blood vessels. Modified from Ref. 18. 
centrations.8,51 Thus, at sites where platelets and/or the 
coagulation cascade are activated, potent vasodilators, 
inhibitors of platelet function and stimulators of fibri­
nolysis are released which may provide a local protec­
tive mechanism against vasospasm, ischemia and 
thrombus formation. 
It is likely that besides EDRF and PGI 2 the endothe­
lium releases an endothelium-derived hyperpolarizing 
factor (EDHF) (Figure l ) . 5 2 In the canine femoral artery, 
endothelium-dependent relaxations to acetylcholine are 
reduced after inhibition of sodium-potassium ATPase 
by ouabain.5 3 Acetylcholine causes endothelium-de­
pendent increases in membrane potential of vascular 
smooth muscle cells which can be blocked by ouabain.5 4 
Exogenous nitric oxide, however, does not hyperpolar-
ize vascular smooth muscle cells nor does hemoglobin 
prevent the increase in membrane potential evoked by 
acetylcholine.55 Thus, another substance must be in­
volved. Endothelium-dependent hyperpolarization of 
vascular smooth muscle cells may facilitate relaxation 
and attenuate the responsiveness of the vascular wall to 
certain vasoconstrictor hormones. 
Endothelium-derived Contracting Factors Endothe­
lial cells are also a source of contracting factors (EDCF) 
(Figure l ) . 3 - 4 ' 7 ' 1 2 - 1 5 Endothelial cells in culture produce a 
vasoconstrictor which has recently been characterized 
as the 21 amino acid peptide endothelin by Yanagisawa 
et al (Figure 3 ) . 1 5 ' 5 6 - 5 7 Three forms of the peptide exist, 
endothelin-1 (formerly human or porcine), endothelin-
2 and endothelin-3 (formerly rat endothelin). 5 8 - 6 0 
Thrombin, epinephrine, transforming growth factor /?, 
the calcium ionophore A23187 and phorbol ester ex­
press preproendothelin messenger RNA in cultured en­
dothelial cells (Figure 3 ) . 1 5 5 8 - 6 0 Thrombin releases en­
dothelin from porcine endothelial cells in culture.6 1 A 
putative converting enzyme cleaves the final peptide 
from its precursor (proendothelin). Endothelin binds to 
specific membrane receptors on vascular smooth muscle 
cells where it activates phospholipase C (and in turn 
stimulates the formation of inositol trisphosphate and 
diacylglycerol),6 2 6 3 phospholipase A 2 , 6 4 increases intra­
cellular calcium and evokes long-lasting contrac­
tions. 1 5 , 6 5 In isolated arteries, endothelin is a very potent 
vasoconstrictor with a half-maximal effective concen­
tration which is one to two orders of magnitude lower 
than that of angiotensin II and norepinephrine.1 5 ' 6 6" 6 8 
When infused in vivo, endothelin causes a rapid and 
transient decrease in blood pressure followed by pro­
longed hypertension. 1 5 6 9 , 7 0 The vasodilator action of 
endothelin has been attributed to the release of PGI 2 
and/or EDRF. 7 1 While EDRF, nitrovasodilators and iso­
proterenol can reverse endothelin-induced contrac­
tions, calcium antagonists are less effective in most vas­
cular preparations. 1 5 , 6 5 ' 6 8 , 7 2 ' 7 3 
In the canine coronary artery, hypoxia causes endo­
thelium-dependent contractions.1 3 It is unlikely that the 
endothelium-derived contracting factor released under 
these conditions (EDCFj) is endothelin, since the re-
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sponse to hypoxia is faster and can be prevented by 
calcium antagonists. 7 3 Indeed, endothelin is not stored 
in endothelial cells. 1 5 
In addition, the endothelium and vascular wall pos­
sess an independent renin - angiotensin system which 
may provide high local concentrations of the potent va­
soconstrictor angiotensin II (Figure l ) . 7 Thromboxane 
A 2 and another cyclooxygenase-dependent endothe­
lium-derived contracting factor (EDCF 2) can also be 
produced in endothelial cells of certain vascular beds 
(Figure 1) . 3 < 4 ' 1 4 ' 7 4 
ENDOTHELIUM AND BLOOD 
PRESSURE CONTROL 
It is likely that the endothelium contributes to the regu­
lation of peripheral vascular resistance. Indeed, infusion 
of hemoglobin — an inhibitor of EDRF 2 4 —in healthy 
human subjects increases arterial blood pressure.7 5 Sim­
ilarly, infusion of L-N-monomethylarginine, a false pre­
cursor substance of EDRF, 3 4 - 3 5 increases blood pressure 
in experimental animals (Figure 4 ) . 7 6 Endothelium-de­
pendent contractions to stretch 7 4 , 7 7 may contribute to 
autoregulation. Intravenous infusion of endothelin 
causes profound and longlasting increases in peripheral 
vascular resistance and blood pressure. 1 5 ' 6 9 - 7 1 
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FIGURE 4. Effect of L-NG-monomethyl arginine (L-NMMA; 
100 mg/kg, intravenously) on blood pressure (B.P.) and heart rate 
(H.R.) in the anesthetized rabbit. L-NMMA evokes a marked and 
sustained rise in blood pressure and a slight decrease in heart rate 
(A). Infusion of L-arginine reverses the effects of L-NMMA (B). 
From Ref. 76, by permission. 
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The circulating levels of endothelin-1 in healthy nor­
mal subjects, however, are very low (ie, 1.5 pg/mL). 7 8 , 7 9 
Hence it is likely that the peptide exerts its action locally 
and/or that it is secreted primarily towards the ablu-
minal side of the blood vessel wall. Even subthreshold 
concentrations of the peptide may, by potentiating the 
effects of norepinephrine, contribute to the regulation 
of blood pressure. 8 0 - 8 2 Thus, alterations in the release of 
endothelium-derived relaxing and contracting factors in 
hypertension may contribute to the increased peripheral 
vascular resistance. 
ENDOTHELIUM-DEPENDENT RESPONSES 
IN HYPERTENSION 
Endothelium-dependent Relaxations Acute and se­
vere increases in blood pressure can cause endothelial 
damage. 8 3 In the canine coronary artery, this is asso­
ciated with an endothelium-dependent enhancement of 
the vasoconstrictor effects to serotonin, while the relax­
ations to acetylcholine are unaffected.8 3 In the cat cere­
bral circulation, acute hypertension abolishes endothe­
lium-dependent relaxations to acetylcholine. 8 4 
In the aorta of rats with chronic spontaneous hyper­
tension, renal hypertension, salt-induced hypertension, 
coarctation and DOCA-salt-induced hypertension, en­
dothelium-dependent relaxations to acetylcholine and 
the calcium ionophore A23187 are attenuated (Figure 
5 ^ . 4 , 8 5 - 9 1 similar defects occur in the carotid artery, in 
mesenteric resistance arteries, but not the renal artery of 
the spontaneously hypertensive rat . 9 2 " 9 7 Endothelium-
A c e t y l c h o l i n e , - l o g Μ 
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FIGURE 5. Endothelium-dependent relaxations to acetylcho­
line in the aorta of normotensive Wistar-Kyoto rats (WKY; top 
panel) and spontaneously hypertensive rats (SHR; lower panel). 
Note the reduced relaxation in the SHR. Original recording, from 
Luscher and Vanhoutte 1988, by permission. 
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dependent relaxations are impaired regardless of the 
agonist used to contract the resistance arteries (norepi­
nephrine, serotonin or endothelin). 9 5" 9 8 In the forearm 
circulation of hypertensive patients, the vasodilator re­
sponse to acetylcholine, but not that to sodium nitro-
prusside, is reduced. 9 9 , 1 0 0 
The reduction of endothelium-dependent relaxations 
to acetylcholine is directly related to the level of systolic 
blood pressure (Figure 6 ) . 4 , 9 0 , 1 0 1 In the Dahl rat, antihy­
pertensive therapy normalizes blood pressure and the 
attenuated endothelium-dependent relaxations. 1 0 2 In 
rats with aortic coarctation endothelium-dependent re­
laxations are normal in the aortic segment distal to the 
stenosis suggesting that the defect is a consequence 
rather than a cause of the high blood pressure.9 1 In the 
spontaneously hypertensive rat, endothelium-depen­
dent responses become progressively impaired as blood 
pressure increases. 9 4 1 0 3 Whether or not this defect is 
secondary or primary in nature remains to be deter­
mined. 
In contrast to the rat, endothelium-dependent relax­
ations to acetylcholine are augmented in the aorta and in 
the perfused hindlimb of mice with psychosocial hyper­
tension.104 Similar results have been reported in the 
femoral artery of the spontaneously hypertensive rat. 8 5 
In the hindlimb circulation of the rabbit, hypertension 
does not induce marked changes in vascular reactivity; 
the maximal relaxation evoked by acetylcholine, how­
ever, is reduced. 1 0 5 Whether or not these differences 
between rats, mice and rabbits are related to differences 
in the severity, duration or form of hypertension, or due 
to species differences, remains to be clarified. 
As regards to the sequellae of hypertension, an in­
creased interaction between circulating blood cells and 
the blood vessel wall are of particular interest (Figure 
3 ) . 3 , 4 Indeed, hypertension is associated with an in­
creased adherence of granulocytes, monocytes and lym­
phocytes to the endothelium. 1 8 1 0 6 In cerebral arteries of 
the spontaneously hypertensive rat, the adhesion of 
platelets to the endothelium is augmented. 1 0 7 Endothe­
lium-dependent relaxations to adenosine diphosphate 
— which is released from aggregating platelets 3 , 4 ' 4 1 — 
are impaired in the aorta 1 0 8 and carotid artery 9 0 , 9 2 of 
hypertensive rats. Endothelium-dependent relaxations 
to thrombin are markedly reduced in Dahl hyperten­
sive, but not in spontaneously hypertensive rats . 9 0 , 1 0 8 In 
the aorta of normotensive rats, the contractions evoked 
by aggregating platelets are inhibited by the endothe­
lium, while in spontaneously hypertensive rats the in­
hibitory capacity of the endothelium against platelet-in­
duced contractions is attenuated indicating an impaired 
protective function of the endothelium. 1 0 8 This is partic­
ularly unfavorable, since hypertensive platelets are 
preactivated and aggregate more readily to various stim­
uli than those of normotensive controls. 1 0 9 
Endothelium-dependent Contractions Aortic rings 
from normotensive rats contract in response to stretch, a 
response which is augmented in DOCA-hypertensive 
animals (Figure 7 ) . 7 7 The stretch-induced contraction 
can be inhibited by calcium antagonists and by removal 
of the endothelium suggesting that hypertension pro­
motes stretch-induced endothelium-dependent con­
tractions. 
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FIGURE 6. Correlation between 
systolic blood pressure and the con­
centration of acetylcholine needed 
to induce a half maximal relaxation 
in the aorta of Dahl salt-sensitive 
(circles) and salt-resistant rats 
(squares) on either a high (8°/o NaCl; 
closed symbols) or low salt diet 
(0.1°/o NaCl; open symbols). These 
experiments demonstrate that endo­
thelium-dependent relaxations be­
come progressively impaired as 
blood pressure rises. Data from Ref. 
102, by permission. 
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FIGURE 7. Endothelium-dependent contractions to stretch in 
the aorta of normotensive (CONT.) and hypertensive rats (DOCA). 
The response is absent in calcium free solution (Ca = 0) and is 
augmented in the hypertensive animals. From Ref 77, by permis­
sion of the American Heart Association. 
Acetylcholine causes endothelium-dependent con­
tractions in the aorta of the adult spontaneously hyper­
tensive rat, but not in normotensive Wistar-Kyoto rats of 
the same age (Figure 8 ) . 8 7 1 1 0 1 1 1 In old rats (12 months of 
age), when the contractions become most pronounced 
in the hypertensive animals, acetylcholine does evoke 
endothelium-dependent contractions in normotensive 
rats as well suggesting that endothelium-dependent 
contractions reflect the premature aging of the hyper­
tensive arterial wall. 1 1 2 
The endothelium-dependent contractions to acetyl­
choline occur with higher concentrations of acetylcho­
line than those needed to release EDRF. 8 7 Endothelium-
dependent contractions to acetylcholine can be 
prevented by inhibitors of phospholipase A 2 and cy-
clooxygenase suggesting that the metabolism of arachi-
donic acid is involved (Figures 8 and 9 ) . 8 7 Similarly, in 
mesenteric resistance arteries of spontaneously hyper­
tensive rats, endothelium-dependent relaxations to ace­
tylcholine are reversed at higher concentrations and this 
can be prevented by inhibitors of cyclooxygenase.9 6 , 9 7 
The metabolite of arachidonic acid is not likely to be 
prostacyclin, since inhibitors of prostacyclin synthetase 
are ineffective.8 7 In the perfused aorta, small amounts of 
prostaglandin F 2 a , E 2 and—in the spontaneously hy­
pertensive rat — of thromboxane B 2 are released.114 
Thromboxane receptor antagonists, but not thrombox­
ane synthetase inhibitors, however, inhibit the contrac­
tions suggesting that a cyclooxygenase product other 
than thromboxane activates the receptor. 1 1 1 The fact 
that attempts to bioassay the endothelium-derived con­
tracting factor (EDCF 2) released by acetylcholine have 
failed, indicates that a very labile substance such as en-
doperoxide intermediates or oxygen-derived free radi­
cals must be involved or that the substance is only re­
leased towards the abluminal side of the blood vessel 
wall. Superoxide radicals contract the rat aorta and the 
response is augmented in hypertension. 1 1 0 Scavengers 
of oxygen-derived free radicals such as superoxide dis-
mutase do not prevent endothelium-dependent con­
tractions to acetylcholine as they do in brain blood ves­
sels. 1 1 0 Thus, the nature of this endothelium-derived 
relaxing factor (EDCF 2) remains elusive. 
In the aorta of the spontaneously hypertensive rat, 
the contractions evoked by aggregating platelets are en­
hanced in rings with, but not in those without, endothe­
lium. 1 0 8 Serotonin exerts similar effects, particularly if 
5HT2-serotonergic receptors of the vascular smooth 
muscle are blocked by ketanserin to unmask the endo­
thelial effects of the monoamine. 1 0 8 Serotonin increases 
coronary flow and dilates cerebral microvessels of nor­
motensive rats, but decreases coronary flow and con­
stricts cerebral microvessels in hypertensive rats. 1 1 4 1 1 5 
This effect of serotonin in the hypertensive coronary 
and cerebral circulation can be inhibited by indometha­
cin. Inhibition of cyclooxygenase also normalizes the 
attenuated vasodilator effects of adenosine diphosphate 
in hypertensive cerebral microvessels. These results are 
consistent with the concept that in hypertension an en­
dothelium-derived contracting factor dependent on cy­
clooxygenase (EDCF 2) is released in response to plate­
let-derived products which offsets the effects of EDRF. 
Whether or not these altered responses to platelet-de­
rived products contribute to the increased peripheral 
vascular resistance in hypertension is uncertain. How­
ever, it may relate to the vascular complications such as 
ischemic stroke, myocardial infarction and peripheral 
vascular disease.4 
Causes of Endothelial Dysfunction The alterations of 
endothelium function differ in different vascular beds 
and different models of hypertension.4 Hypertension 
can interfere with the release and/or action of endothe­
lial substances. As judged from bioassay experiments in 
the rat aorta, the luminal release of EDRF and PGI2 
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induced by acetylcholine or histamine is normal in 
spontaneous, renal and DOCA-salt hyperten­
s ion . 1 1 3 1 1 6 1 1 7 A reduced abluminal release of the factor, 
however, remains a possibility. Indirect evidence sug­
gests that in the human forearm and in salt-induced 
hypertension of the rat the release of EDRF might be 
reduced. 9 0 " 1 0 0 Whether or not the basal release of the 
factor is decreased in the spontaneously hypertensive 
rat is uncertain. 1 1 3 1 1 7 
Subendothelial thickening of the hypertensive blood 
vessel wal l 1 9 " 2 3 is unlikely to interfere with the diffusion 
of EDRF towards vascular smooth muscle. Indeed, if a 
diffusion barrier were important, a parallel right-ward 
shift of the concentration response curve to acetylcho­
line should be expected. However, endothelium-de­
pendent relaxations are most prominently impaired at 
higher concentrations of the agonists (Figure 5 ) . 8 5 " 9 1 
Further, extensive intimal thickening does not interfere 
with endothelium-dependent relaxations in the carotid 
artery of normotensive rabbits. 1 1 8 
Sodium nitroprusside — which, like EDRF, activates 
guanylate cyclase 3 0 — has been used to assess the re­
sponsiveness of hypertensive blood vessels to EDRF. 4 
Normal, reduced and enhanced relaxations to sodium 
nitroprusside have been repor ted . 8 5 - 9 7 ' 1 1 9 , 1 2 0 Differences 
in the anatomical location of the blood vessel, the age of 
the animal and of the duration, severity and form of 
hypertension may be important. Indeed, in the aorta of 
the rat, the relaxations to sodium nitroprusside and so­
dium nitrate decrease with age. 1 2 0 The presence of endo­
thelial cells inhibits the effects of nitrovasodilators and 
in the aorta of the spontaneously hypertensive rat and 
this accounts at least in part for the reduced response. 1 2 0 
In the carotid artery and in the aorta of these animals the 
relaxations to sodium nitroprusside are impaired, while 
in the renal and in hypertensive mesenteric resistance 
arteries, the response is not attenuated. 9 4 , 9 5 , 9 7 Thus, de­
pressed endothelium-dependent relaxations do occur in 
hypertensive arteries even in the presence of a normal 
response to nitrovasodilators indicating a predominant 
endothelial defect. 
In the aorta of the spontaneously hypertensive rat, 
endothelium-dependent relaxations are decreased due 
to the simultaneous occurrence of endothelium-depen-
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FIGURE 9. Effect of indomethacin (to inhibit the formation of 
vascular prostaglandins) on endothelium-dependent relaxations 
to acetylcholine in the aorta of normotensive (WKY; dashed lines) 
and spontaneously hypertensive (SHR; solid lines) rats. These ex­
periments demonstrate that indomethacin can normalize the re­
duced endothelium-dependent relaxations in the aorta of the SHR. 
From Ref 87, by permission of the American Heart Association. 
dent contractions which can be blocked by indometha­
cin (Figure 9 ) . 8 7 In the aorta of the Dahl rat, 9 0 in the 
carotid artery of the spontaneously hypertensive rat 9 2 
and most likely also in the forearm circulation of hyper­
tensive patients, 1 0 0 a cyclooxygenase-dependent endo-
thelium-derived relaxing factor (EDCF 2) is not released 
by acetylcholine, since the response to the muscarinic 
agonist is unaffected by indomethacin. In these blood 
vessels, the predominant lesion appears to be a reduced 
production and/or attenuated responsiveness to EDRF. 
Locally generated endothelin would—if produced in 
sufficient amounts in v i v o 7 8 7 9 — attenuate endothe­
lium-dependent relaxations in hypertensive arteries, 
while in normotensive rats EDRF inhibits the contractile 
effects of the peptide. 9 8 This imbalance between endo-
thelium-derived relaxing and contracting factors would 
be most pronounced in arteries with an augmented sen­
sitivity to the peptide, such as the renal artery of the 
spontaneously hypertensive rat. 1 2 1 
ATHEROSCLEROSIS 
Although in the rat hypertension is associated with mor­
phological changes of the endothelium—in contrast to 
atherosclerosis — intimal lipid accumulation does not 
occur in the absence of hyperlipoproteinemia.1 0 6 1 2 2 In 
men, however, hypertension and hyperlipidemia are 
major risk factors for the development of atherosclerotic 
vascular disease and they are often associated in the 
same patient. In the rabbit aorta low-density lipopro­
teins (LDL), but not high-density lipoproteins (HDL), 
inhibit endothelium-dependent relaxations to acetyl­
choline. 1 2 3 In cultured endothelial cells LDL interferes 
with the basal and receptor-operated release of 
EDRF. 1 2 4 1 2 5 A reduced production of EDRF would be 
associated with an increased adherence of platelets to 
the vessel wall 9 and in turn locally increased levels of 
platelet-derived growth factor (PDGF). 1 2 2 This would 
promote vascular growths particularly since EDRF may 
act as a antiproliferative factor. 1 2 6 Thus, a reduced re­
lease of EDRF 1 2 7 may also contribute to the formation of 
the atherosclerotic plaque. In atherosclerotic arteries, 
including the human coronary artery, endothelium-de­
pendent relaxations to acetylcholine, adenosine diphos­
phate, bradykinin, substance Ρ and aggregating plate­
lets are reduced (Figure ίο). 4 7 1 2 8 - 1 3 1 Selective infusion 
of acetylcholine into the left anterior descending coro­
nary artery causes paradoxical contractions in patients 
with coronary artery disease. 1 3 2 A reduced release of 
EDRF, structural changes of the intima and media, and 
— at least in the porcine coronary artery — the produc­
tion of an endothelium-derived contracting factor 
(EDCF 2) contribute to these changes in atherosclerotic 
ar ter ies . 4 ' 4 7 1 2 7 " 1 3 2 Thus, hypertension and hyperlipide­
mia are associated with an imbalance of endothelium-
derived relaxing and contracting factors and this may 
reduce the antispastic, antithrombotic and antiprolifera­
tive properties of the endothelial layer. Thus, endothe­
lium dysfunction may represent a common denomina­
tor of vascular injury induced by cardiovascular risk 
factors. 
ANTIHYPERTENSIVE THERAPY AND 
VASCULAR PROTECTION 
A normalization of endothelium-dependent relaxations 
with antihypertensive therapy 1 0 1 1 0 2 might contribute to 
the ability of the drugs to prevent or reduce cardiovascu­
lar complications of hypertension. In Dahl rats with 
salt-induced hypertension, reserpine, hydrochlorothia­
zide and hydralazine normalize blood pressure and the 
attenuated endothelium-dependent relaxations to ace­
tylcholine, adenosine diphosphate and thrombin.1 0 2 
Changes in transmural pressure during antihyperten­
sive therapy must play an important role, since the ef­
fect is related to the degree of blood pressure reduc­
t ion . 4 1 0 1 The inhibitor of converting enzyme enalapril, 
which does not lower blood pressure in Dahl rats, does 
not affect endothelium-dependent relaxations.4 On the 
other hand, in the aorta of the rabbit, but not in that of 
the rat, the relaxations induced by hydralazine are in 
part endothelium-dependent.1 3 3 Chronic therapy with 
captopril or hydralazine, but not with enalapril, aug­
ments endothelium-dependent relaxations to acetyl­
choline even in normotensive rats. 1 3 4 Thus, changes in 
transmural pressure and—at least in part — direct pro-
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Monkey iliac arteries Rabbit aortas 
FIGURE 10. Endothelium-de­
pendent relaxations to acetylcholine 
in atherosclerotic arteries. Athero­
sclerosis was induced by a high cho­
lesterol diet. In the iliac artery of 
atherosclerotic monkeys (left; open 
circles) and in the aorta of rabbits 
with hypercholesteremia (right; 
squares), the response to the musca­
rinic agonist is reduced in prepara­
tions with endothelium. From Ref 4, 
by permission. 
9 8 7 6 5 4 9 8 7 6 
Acety lcho l ine , - log Μ 
F r e i m a n e t a l , 1 9 8 6 V e r b e u r e n e t a l . 1 9 8 6 
tective vascular effects of some drugs restore endothe­
lium-dependent relaxations in hypertension. 
Other factors than high blood pressure can cause 
morphological changes of the intima. Indeed, in the rat, 
the changes are more pronounced with high than with 
low levels of mineralcorticoids. 1 9 , 2 0 In man, high renin 
hypertension is associated with a higher incidence of 
stroke and myocardial infarction than low renin hyper­
tension.135 In hypertensive rats, high dietary sodium is 
an important determinant of intimal injury. 1 3 6 In man, a 
high dietary potassium intake protects against stroke-
associated deaths. 1 3 7 This effect of high dietary potas­
sium is independent of other dietary variables or cardio­
vascular risk factors. Indeed in hypertensive Dahl rats 
high dietary potassium supplementation reduces the in­
cidence of strokes and renal vascular injury indepen­
dent of its effects on blood pressure. 1 3 8 , 1 3 9 High dietary 
potassium supplementation enhances endothelium-de­
pendent relaxations to acetylcholine in hypertensive 
Dahl rats at least in part independently of blood pres­
sure, suggesting a vascular protective effect of the diet 
(Figure l l ) . 1 4 1 
In populations with a high dietary fish consumption 
the death rate from coronary artery disease is low. 1 4 1 In 
the pig, cod-liver oil delays the development of coro­
nary atherosclerosis.1 4 2 This vascular protective effect of 
cod-liver oil is independent of its effects on plasma lipid 
levels and probably mediated primarily by eicosapen-
tanoic ac id . 1 4 1 , 1 4 2 In the coronary artery and in coronary 
microvessels of the pig, dietary supplementation with 
fish oil or eicosapentanoic acid enhances endothelium-
dependent relaxation to platelet-derived products and 
other autocoids. 1 4 3 , 1 4 4 In cultured porcine endothelial 
cells eicosapentanoic acid augments the release of EDRF 
evoked by bradykinin and adenosine diphosphate, but 
not that induced by the calcium ionophore A23187 . 1 4 5 
This may be important both in the prevention of athero-
D S - D R -
rots rots 
• • 0 . 1 % NaCl , n« 12 
ο • 8 % N a C I , n « l 4 o r 8 « » / 5 
ο · 8 % N a C l / 3 . 6 % K + c i t r a t e , n « 6 / 7 
D a h l s a l t - s e n s i t i v e r a t s D a h l s a l t - r e s i s t a n t r a t s 
9 8 7 6 5 4 9 8 7 6 5 4 
A c e t y l c h o l i n e , - l o g Μ 
FIGURE 11. Effects of high dietary potassium supplementation 
on endothelium-dependent relaxations to acetylcholine in the 
aorta of hypertensive Dahl rats. The response is attenuated in rats 
fed high dietary sodium (open diamonds; left). In hypertensive rats 
supplemented with high dietary potassium (8°/o NaCl plus 3.6°/o 
K+ citrate; open circles), endothelium-dependent relaxations are 
augmented both as compared to all hypertensive rats (open dia­
monds) and to a subgroup of rats fed 8% NaCl matched for blood 
pressure (dotted diamonds). DS = Dahl salt-sensitive; DR = Dahl 
salt-resistant. From Ref. 140, by permission of the American Heart 
Association. 
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sclerosis and for the regulation of local blood flow. In­
deed, dietary eicosapentanoic acid lowers blood pres­
sure in people. 1 4 6 
ACKNOWLEDGMENT 
The author wishes to thank Sabine Bohnert and Bernadette 
Libsig, Department of Research, University Hospital, Basel, 
for their assistance. 
REFERENCES 
1. Moncada S, Vane JR: Pharmacology and endogenous 
roles of prostaglandin endoperoxides, thromboxane A 2 
and prostacyclin. Pharmacol Rev 1979;30:293-331. 
2. Furchgott RF, Zawadzki JV: The obligatory role of en­
dothelial cells in the relaxation of arterial smooth mus­
cle by acetylcholine. Nature 1980;299:373-376. 
3. Vanhoutte PM, Rubanyi GM, Miller VM, et al: Modula­
tion of vascular smooth muscle contraction by the en­
dothelium. Ann Rev Physiol 1986;48:307-320. 
4. Luscher TF: Endothelial Vasoactive Substances and 
Cardiovascular Disease. Basel, S. Karger Publisher AG, 
1988, pp 1 - 1 3 3 . 
5. Shepherd JT, Vanhoutte PM: The Human Cardiovas­
cular System. New York, Raven Press, 1979. 
6. Ng KKF, Vane JR: Conversion of angiotensin I to angio­
tensin II. Nature 1967;216:762-766. 
7. Dzau VJ: Significance of the vascular renin-angiotensin 
pathway. Hypertension 1986;8:553-559. 
8. Radomski MW, Palmer RMJ, Moncada S: The anti-ag-
gregating properties of vascular endothelium: interac­
tions between prostacyclin and nitric oxide. Br J Phar­
macol 1987;92:639-646. 
9. Radomski MW, Palmer RMJ, Moncada S: Endogenous 
nitric oxide inhibits human platelet adhesion to vascu­
lar endothelium. Lancet 1987;ii:1057-1068. 
10. Chesterman CN: Vascular endothelium, haemostasis 
and thrombosis. Blood Reviews 1988;2:88-94. 
11. Moncada S, Herman AG, Higgs EA, et al: Differential 
formation of prostacyclin (PGX or PGI 2) by layers of the 
arterial wall. An explanation for the anti-thrombotic 
properties of vascular endothelium. Thrombosis Res 
1977;11:323-344. 
12. De Mey JG, Vanhoutte PM: Anoxia and endothelium-
dependent reactivity in canine femoral artery. J Physiol 
(London) 1983;335;65-74. 
13. Rubanyi GM, Vanhoutte PM: Hypoxia releases a vaso­
constrictor substance from the canine vascular endo­
thelium. J Physiol (London) 1985;364:45-56. 
14. Miller VM, Vanhoutte PM: Endothelium-dependent 
contractions to arachidonic acid are mediated by prod­
ucts of cyclooxygenase in canine veins. Am J Physiol 
1985;248:H432-H437. 
15. Yanagisawa M, Hurihara H, Kimura S, et al: A novel 
potent vasoconstrictor peptide produced by vascular 
endothelial cells. Nature 1988;332:411-415. 
16. Luscher TF, Diederich D, Buhler FR, et al: Interactions 
between platelets and the vessel wall: Role of endothe­
lium-derived vasoactive substances, in Laragh JH, 
Brenner Β (eds): Hypertension: Pathophysiology, Diag­
nosis and Management, New York, Raven Press, 1989, 
pp 6 3 7 - 6 4 8 . 
17. Luscher TF, Yang Z, Diederich D, et al: Endothelium-
derived vasoactive substances: potential role in hyper­
tension and atherosclerosis and vascular occlusion. 
J Cardiovasc Pharmacol 1989;14(suppl 6 ) :63-69 . 
18. Luscher TF: Endothelium-derived relaxing and con­
tracting factors: potential role in coronary artery dis­
ease. Eur Heart J 1989;10:847-857. 
19. Gabbiani G, Glemes G, Guelpa C, et al: Morphologic 
and functional changes of the aortic intima during ex­
perimental hypertension. Am J Pathol 1979,96:399-
422. 
20. Huttner I, Gabbiani G: Vascular endothelium in hyper­
tension, in Genest J, Kuchel O, Hamet P, Cantin Μ 
(eds): Hypertension. New York, McGraw-Hill, 1983, 
pp 4 7 3 - 4 8 8 . 
21. Limas C, Westrum B, Iwai J, et al: Aortic morphology in 
salt-dependent genetic hypertension. Am J Pathol 
1982;107:378-394. 
22. McGuire PG, Twietmeyer Τ A: Aortic endothelial junc­
tions in developing hypertension. Hypertension 
1985;7:483-490. 
23. Haudenschild CC, Prescott MF, Chobanian AV: Effects 
of hypertension and its reversal on aortic intima lesions 
of the rat. Hypertension 1979;2:33-44. 
24. Martin W, Villani GM, Jothianandan D, et al: Blockade 
of endothelium-dependent and glyceryl trinitrate-in-
duced relaxation of rabbit aorta by certain ferrous he-
moproteins. J Pharmacol Exp Ther 1985;233:679-685. 
25. Rubanyi GM, Lorenz RR, Vanhoutte PM: Bioassay of 
endothelium-derived relaxing factor(s): inactivation by 
catecholamines. Am J Physiol 1985;249:H95-H101. 
26. Rubanyi GM, Vanhoutte PM: Superoxide anions and 
hyperoxia inactivate endothelium-derived relaxing fac­
tor. Am J Physiol 1986;250:H822-H827. 
27. Gryglewski RJ, Palmer RMJ, Moncada S: Superoxide 
anion is involved in the breakdown of endothelium-de­
rived vascular relaxing factor. Nature 1986,320:454-
456. 
28. Moncada S, Palmer RMJ, Grygewski RJ: Mechanism of 
action of some inhibitors of endothelium-derived re­
laxing factor. Proc Natl Acad Sci 1986;83:9164-9168. 
29. Busse R, Luckhoff A, Bassenge E: Endothelium-derived 
relaxant factor inhibits platelet activation. Naunyn-
Schmiedeberg's Arch Pharmacol 1987;336:566-571. 
30. Rapoport RM, Draznin MB, Murad F: Endothelium-de­
pendent relaxation in rat aorta may be mediated 
through cyclic GMP-dependent protein phosphoryla­
tion. Nature 1983;306:174-176. 
31. Furchgott RF: Studies on relaxation of rabbit aorta by 
sodium nitrite: the basis for the proposal that acid-acti-
vatable inhibitory factor from bovine retractor penis is 
inorganic nitrite and the endothelium-derived relaxing 
factor is nitric oxide, in Vanhoutte PM (ed): Vasodilata­
tion. New York, Raven Press, 1988, pp 4 0 1 - 4 1 4 . 
32. Ignarro LJ, Byrns RE, Wood KS: Pharmacological and 
biochemical properties of endothelium-derived relax­
ing factor (EDRF): evidence that it is closely related to 
nitric oxide (NO) radical (abstr). Circulation 1986; 
74(suppl II):287. 
AJH-APRIL 1990-VOL 3, NO. 4 E N D O T H E L I U M I N H Y P E R T E N S I O N 327 
33. Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide re­
lease accounts for the biological activity of endothe-
lium-derived relaxing factor. Nature 1987;327:524-
526. 
34. Palmer RMJ, Ashton DS, Moncada S: Vascular endo­
thelial cells synthesize nitric oxide from L-arginine. Na­
ture 1988;333:664-666. 
35. Palmer RMJ, Moncada S: A novel citrulline-forming 
enzyme implicated in the formation of nitric oxide by 
vascular endothelial cells. Biochem Biophys Res Comm 
1989;158:348-352. 
36. Rubanyi GM, Romero JC, Vanhoutte PM: Flow-in­
duced release of endothelium-derived relaxing factor. 
Am J Physiol 1986;250:H1145-H1149. 
37. Pohl U, Holtz J, Busse R, et al: Crucial role of endothe­
lium in the vasodilator response to increased flow in 
vivo. Hypertension 1986;8:37-44. 
38. De Mey JG, Claeys M, Vanhoutte PM: Endothelium-
dependent inhibitory effects of acetylcholine, adeno­
sine diphosphate, thrombin and arachidonic acid in the 
canine femoral artery. J Pharm Exp Ther 1982; 
2 2 2 : 1 6 6 - 1 7 3 . 
39. Cohen RA, Shepherd JT, Vanhoutte PM: Inhibitory role 
of the endothelium in the response of isolated coronary 
arteries to platelets. Science 1983;221:273-274. 
40. Cohen RA, Shepherd JT, Vanhoutte PM: 5-Hydroxy-
tryptamine can mediate endothelium-dependent relax­
ations of coronary arteries. Am J Physiol 1983; 
245:H1077-H1080. 
41. Houston DS, Shepherd JT, Vanhoutte PM: Adenine 
nucleotides, serotonin and endothelium-dependent re­
laxations to platelets. Am J Physiol 1985;248:H389-
H395. 
42. Cocks TM, Angus JA, Campbell JH, et al: Release and 
properties of endothelium-derived relaxing factor 
(EDRF) from endothelial cells in culture. J Cell Physiol 
1985;123:310-320. 
43. Van de Voorde J, Leusen I: Role of the endothelium in 
the vasodilator response of rat thoracic aorta to hista­
mine. Eur J Pharmacol 1983;87:113-120. 
44. Cocks TM, Angus JA: Endothelium-dependent relax­
ation of coronary arteries by noradrenaline and sero­
tonin. Nature 1983;305:627-630. 
45. Zawadzki JV, Furchgott RF, Cherry P: The obligatory 
role of endothelial cells in the relaxations of arterial 
smooth muscle by substance Ρ (abstr). Fed Proc 
1981;40:689. 
46. Katusic ZS, Shepherd JT, Vanhoutte PM: Vasopressin 
causes endothelium-dependent relaxations of the ca­
nine basilar artery. Circ Res 1984;55:575-579. 
47. Forstermann U, Mugge A, Bode SM, et al: Response of 
human coronary arteries to aggregating platelets: im­
portance of endothelium-derived relaxing factor and 
prostanoids. Circ Res 1988;63:306-312. 
48. Shimokawa H, Aarhus LL, Vanhoutte PM: Porcine cor­
onary arteries with regenerated endothelium have a 
reduced endothelium-dependent responsiveness to ag­
gregating platelets and serotonin. Circ Res 1987; 
61 :256 -270 . 
49. Luscher TF, Cooke JP, Houston DS, et al: Endothelium-
dependent relaxations in human peripheral and renal 
arteries. Mayo Clin Proc 1987;62:601-606. 
50. Luscher TF, Diederich D, Siebenmann R, et al: Differ­
ence between endothelium-dependent relaxations in 
arterial and in venous coronary bypass grafts. Ν Engl J 
Med 1988;319:462-467. 
51. Shimokawa H, Flavahan NA, Lorenz RR, et al: Prosta­
cyclin releases endothelium-derived relaxing factor and 
potentiates its action in coronary arteries of the pig. Br J 
Pharmacol 1988;95:1197-1203. 
52. Vanhoutte PM: The end of the quest? Nature 
1987;327:459-460. 
53. De Mey J, Vanhoutte PM: Role of Na + , K+-ATPase in 
the vasodilator response to acetylcholine, in: Vanhoutte 
PM, Leusen I (eds): Vasodilatation. New York, Raven 
Press, 1981, pp 3 3 1 - 3 3 7 . 
54. Feletou M, Vanhoutte PM: Endothelium-dependent 
hyperpolarization of canine coronary smooth muscle. 
Br J Pharmacol 1988;93:515-524. 
55. Komori K, Lorenz RR, Vanhoutte PM: Nitric oxide, ace­
tylcholine, and electrical and mechanical properties of 
canine arterial smooth muscle. Am J Physiol 
1988;255:H207-H212. 
56. Hickey KA, Rubanyi GM, Paul RJ, et al: Characteriza­
tion of a coronary vasoconstrictor produced by cultured 
endothelial cells. Am J Physiol 1985;248:C550-C556. 
57. Gillespie MN, Owasoyo JO, McMurtry IF, et al: Sus­
tained coronary vasoconstriction provoked by a pepti­
dergic substance released from endothelial cells in cul­
ture. J Pharm Exp Ther 1986;236:339-343. 
58. Masaki T: The discovery, the present state, and the fu­
ture prospects of endothelin. J Cardiovasc Pharmacol 
1989;13(suppl 5 ) : l - 4 . 
59. Yanagisawa M, Inoue A, Takuwa Y, et al: The human 
preproendothelin gene: possible regulation by endo­
thelial phosphoinositide turnover signaling. J Cardio­
vasc Pharmacol 1989;13(suppl 5) :13-17 . 
60. Yanagisawa M, Inoue A, Ishikawa T, et al: Primary 
structure, synthesis, and biological activity of rat 
endothelin, an endothelium-derived vasoconstrictor 
peptide. Proc Natl Acad Sci USA 1988,85:6964-
6967. 
61. Schini VB, Hendrickson H, Heublein DM, et al: Throm­
bin enhances the release of endothelin from cultured 
porcine aortic endothelial cells. Eur J Pharmacol 1989; 
(in press). 
62. Hirata Y, Yoshimi H, Takata S, et al: Cellular mecha­
nism of action by a novel vasoconstrictor endothelin in 
cultured rat vascular smooth muscle cells. Biochem 
Biophys Res Comm 1988;154:868-875. 
63. Resink TJ, Scott-Burden T, Buhler FR: Endothelin stim­
ulates phospholipase C in cultured vascular smooth 
muscle cells. Biochem Biophys Res Comm 1989; 
157:1360-1368 . 
64. Resink TJ, Scott-Burden T, Buhler FR: Activation of 
phospholipase A 2 by endothelin in cultured vascular 
smooth muscle cells. Biochem Biophys Res Comm 
1989;158:279-286. 
65. Wallnoef er A, Weir S, Ruegg U, et al: The mechanism of 
action of endothelin-1 as compared with other agonists 
328 LUSCHER 
in vascular smooth muscle. J Cardiovasc Pharmacol 
1989;13(suppl 5 ) :23 -31 . 
66. Brain SD, Crossman DC, Buckley TL, et al: Endothelin-
1: demonstration of potent effects on the microcircula­
tion of humans and other species. J Cardiovasc Phar­
macol 1989;13(suppl 5 ) :147-149 . 
67. Hiley CR, Douglas SA, Randall MD: Pressor effects of 
endothelin-1 and some analogs in the perfused supe­
rior mesenteric arterial bed of the rat. J Cardiovasc 
Pharmacol 1989;13(suppl 5 ) :197-199 . 
68. Yang Z, Buhler DR, Diederich D, et al: Different effects 
of endothelin-1 on cAMP- and cGMP-mediated vascu­
lar relaxation in human arteries and veins: comparison 
with norepinephrine. J Cardiovasc Pharmacol 1989; 
13(suppl 5 ) :129-131 . 
69. Watanabe TX, Kumagaye S-I, Nishio H, et al: Effects of 
endothelin-1 and endothelin-3 on blood pressure in 
conscious hypertensive rats. J Cardiovasc Pharmacol 
1989;13(suppl 5 ) :207-208 . 
70. Clarke JG, Larkin SW, Benjamin N, et al: Endothelin-1 
is a potent long-lasting vasoconstrictor in dog periph­
eral vasculature in vivo. J Cardiovasc Pharmacol 
1989;13(suppl 5 ) :211-212 . 
71. deNucci G, Thomas R, DOrleans-Juste P, et al: Pressor 
effects of circulating endothelin are limited by its re­
moval in the pulmonary circulation and by the release 
of prostacyclin and endothelium-derived relaxing fac­
tor. Proc Natl Acad Sci USA 1988;85:9797-9800. 
72. Yang Z, Richard V, Luscher TF: unpublished observa­
tion, 1989. 
73. Vanhoutte PM, Auch-Schwelk W, Boulanger C, et al: 
Does endothelin-1 mediate endothelium-dependent 
contractions curing anoxia? J Cardiovasc Pharmacol 
1989;13(suppl 5 ) :124-128 . 
74. Katusic ZS, Shepherd JT, Vanhoutte PM: Endothelium-
dependent contractions to stretch in canine basilar ar­
teries. Am J Physiol 1987a;252:H671-H673. 
75. Savitzky JP, Doczi J, Black J, Arnold JD: A clinical safety 
trial of stroma-free hemoglobin. Clin Pharmacol Ther 
1978;23:73-80. 
76. Rees DD, Palmer RMJ, Moncada S: Role of endothe­
lium-derived nitric oxide in the regulation of blood 
pressure. Proc Natl Acad Sci USA 1989;86:3375-3378. 
77. Rinaldi G, Bohr D. Endothelium-mediated spontane­
ous response in aortic rings of deoxycorticosterone ace­
tate-hypertensive rats. Hypertension 1989; 13 :256-
261. 
78. Suzuki N, Matsumoto H, Kitada C, et al: Immunoreac­
tive endothelin-1 in plasma detected by a sandwich-
type enzyme immunoassay. J Cardiovasc Pharm 
1989;13(suppl 5 ) :151-153 . 
79. Ando K, Hirata Y, Schichiri M, et al: Presence of immu­
noreactive endothelin in human plasma. FEBS Lett 
1989;245:164-166. 
80. Tabuchi Y, Nakamaru M, Rakugi H, et al: Endothelin 
enhances adrenergic vasoconstriction in perfused rat 
mesenteric arteries. Biochem Biophys Res Comm 
1989;159:1304-1308. 
81. Godfraind T, Mennig D, Morel N, Wibo M: Effect of 
endothelin-1 on calcium channel gating by agonists in 
AJH-APRIL 1990-VOL 3, NO. 4 
vascular smooth muscle. J Cardiovasc Pharmacol 
1989;13(suppl 5) :112-117. 
82. Yang Z, Richard V, Von Segesses L, et al: Endothelin-1 
potentiates contractions to norepinephrine and sero­
tonin in human mammary and coronary arteries (abst). 
J Amer Coll Cardiol (in press). 
83. Lamping KG, Dole WP: Acute hypertension selectively 
potentiates constrictor responses of large coronary ar­
teries to serotonin by altering endothelial function in 
vivo. Circ Res 1987;61:904-913. 
84. Kontos HA: Oxygen radicals in cerebral vascular injury. 
Circ Res 1985;57:508-516. 
85. Konishi M, Su C: Role of endothelium in dilator re­
sponses of spontaneously hypertensive rat arteries. 
Hypertension 1983;5:881-886. 
86. Winquist RJ, Bunting PB, Baskin EP, et al: Decreased 
endothelium-dependent relaxation in New Zealand ge­
netic hypertensive rats. J Hypertens 1984;2:536-541. 
87. Luscher TF, Vanhoutte PM: Endothelium-dependent 
contractions to acetylcholine in the aorta of the sponta­
neously hypertensive rat. Hypertension 1986;8:344-
348. 
88. Van de Voorde J, Cuvelier C, Leusen I: Endothelium-
dependent relaxation effects in aorta from hypertensive 
rats. Arch Int Physiol Biochem 1984;92:P10-P11. 
89. Van de Voorde J, Leusen I: Endothelium-dependent 
and independent relaxation of aortic rings from hyper­
tensive rats. Am J Physiol 1986;250:H711-H717. 
90. Luscher TF, Raij L, Vanhoutte PM: Endothelium-de­
pendent responses in normotensive and hypertensive 
Dahl rats. Hypertension 1987;9:157-163. 
91. Lockette WE, Otsuha Y, Carretero OA. Endothelium-
dependent relaxation in hypertension. Hypertension 
1986;8(suppl II):61-66. 
92. Luscher TF, Diederich D, Vanhoutte PM, et al: Endo­
thelium-dependent responses in the common carotid 
and renal artery of normotensive and spontane­
ously hypertensive rats. Hypertension 1988; 11:573-
578. 
93. Hongo K, Nakagomi T, Kassell NF, et al: Effects of 
aging and hypertension on endothelium-dependent 
vascular relaxation in rat carotid artery. Stroke 1988; 
19:892-897 . 
94. De Mey JG, Gray SD. Endothelium-dependent reactiv­
ity in resistance vessels. Prog Appl Microcirc 
1985;88:181-187. 
95. Tesfamariam B, Halpem W: Endothelium-dependent 
and endothelium-independent vasodilation in resist­
ance arteries from hypertensive rats. Hypertension 
1988;11:440-444. 
96. Luscher TF, Aarhus LL, Vanhoutte PM: Indomethacin 
enhances the impaired endothelium-dependent relax­
ations in small mesenteric arteries of the spontaneously 
hypertensive rat. Am J Hypertens 1990;3:55-59. 
97. Diederich D, Buhler FR, Luscher TF: Endothelium-de­
rived relaxing factor (EDRF) and nitric oxide (NO) in 
mesenteric resistance arteries of normotensive and hy­
pertensive rats (abstr). Hypertension 1988;12:334. 
98. Luscher TF, Diederich D, Yang Z, Buhler FR: Endothe­
lin overrides endothelium-derived relaxing factor in 
AJH-APRIL 1990-VOL 3 , NO. 4 
hypertensive resistance arteries (abstr). Kidney Int 
1989;35(1):331. 
99. Panza JA, Quyyumi AA, Epstein SE: Impaired endothe­
lium-dependent vascular relaxation in hypertensive 
patients (abstr). Circulation 1988;78(suppl II):473. 
100. Linder L, Kiowski W, Biihler FR, Luscher TF: unpub­
lished observation, 1989. 
101. Luscher TF, Raij L, Vanhoutte PM: Effect of hyperten­
sion and its reversal on endothelium-dependent relax­
ations in the rat aorta. J Hypertens 1987;5(suppl 
5 ) :153-155 . 
102. Luscher TF, Vanhoutte PM, Raij L: Antihypertensive 
therapy normalizes endothelium-dependent relax­
ations in salt-induced hypertension of the rat. Hyper­
tension 1987;9(suppl III):193 - 1 9 7 . 
103. Criscione L, Bo well JR, Budet R, Engesser S: Reduced 
endothelium-dependent relaxations in spontaneously 
hypertensive rats is the result not the cause of hyper­
tension (abst). Hochdruck 1988;8:38. 
104. Webb RC, Vander AJ, Henry JP: Increased vasodilator 
responses to acetylcholine in psychosocial hyperten­
sive mice. Hypertension 1987;9:268-276. 
105. Wright CE, Angus J A: Effects of hypertension and hy­
percholesteremia on vasodilatation in the rabbit. Hy­
pertension 1986;8:361-371. 
106. Chobanian AV, Brecher PI, Haudenschild CC: Effects 
of hypertension and of antihypertensive therapy on 
atherosclerosis. Hypertension 1986;8(suppl I): 1 5 - 2 1 . 
107. Hazama F, Ozaki T, Amano S: Scanning electron micro­
scopic study of endothelial cells of cerebral arteries 
from spontaneously hypertensive rats. Stroke 1979; 
10 :245-252 . 
108. Luscher TF, Vanhoutte PM: Endothelium-dependent 
responses to aggregating platelets and serotonin in 
spontaneously hypertensive rats. Hypertension 
1986;8(suppl II):55-60. 
109. De Clerck F: Blood platelets in human essential hyper­
tension. Agents Actions 1986;18:563-580. 
110. Auch-Schwelk W, Katusic Z, Vanhoutte PM: Contrac­
tions to oxygen derived free radicals are augmented in 
the aorta of the spontaneously hypertensive rat. Hy­
pertension 1989;13:859-864. 
111. Auch-Schwelk W, Katusic ZS, Vanhoutte PM: Endo­
thelium-dependent contractions in the SHR aorta are 
inhibited by thromboxane A 2 receptor antagonists 
(abstr). J Vase Med Biol 1989,1:76. 
112. Koga T, Takata Y, Kobayashi K, et al: Age and hyper­
tension promote endothelium-dependent contractions 
to acetylcholine in the aorta of the rat. Hypertension 
1989; (in press). 
113. Luscher TF, Romero JC, Vanhoutte PM: Bioassay of 
endothelium-derived vasoactive substances in the 
aorta of normotensive and spontaneously hypertensive 
rats. J Hypertens 1986;4(suppl 6 ) :81-83 . 
114. Luscher TF, Rubanyi GM, Aarhus LL, et al: Serotonin 
reduces coronary flow in isolated hearts of the sponta­
neously hypertensive rat. J Hypertens 1986;4(suppl 
5 ) :148-150 . 
115. Mayhan WG, Faraci FM, Heistad DD: Impairment of 
endothelium-dependent responses of cerebral arteri-
E N D O T H E L I U M I N H Y P E R T E N S I O N 329 
oles in chronic hypertension. Am J Physiol 1987; 
253:H1435-H1440. 
116. Van de Voorde J, Leusen I: Endothelium-dependent 
and independent relaxation effects on aorta prepara­
tions of renal hypertensive rats. Arch Int Physiol Bio­
chem 1984;92:P35-P36. 
117. Hoeffner U, Vanhoutte PM: Increases in flow reduce 
the release of endothelium-derived relaxing factor in 
the aorta of normotensive and spontaneously hyper­
tensive rats. Am J Hypertens 1989;2:762-767. 
118. Cocks TM, Manderson J A, Mosse PRL, et al: Develop­
ment of a large fibromuscular intimal thickening does 
not impair endothelium-dependent relaxations in the 
rabbit carotid artery. Blood Vessels 1987;24:192-200. 
119. Cohen ML, Berkowitz BA: Decreased vascular relax­
ation in hypertension. J Pharmacol Exp Ther 1976; 
196:396-406 . 
120. Shirasaki Y, Su C, Lee TJ-F, et al: Endothelial modula­
tion of vascular relaxation to nitrovasodilators in aging 
and hypertension. J Pharmacol Exp Ther 1986; 
239:861-866 . 
121. Tomobe Y, Miyauchi T, Saito A, et al: Effects of endoth­
elin on the renal artery from spontaneously hyperten­
sive and Wistar Kyoto rats. Eur J Pharmacol 1988; 
152:373-374 . 
122. Ross R: The pathogenesis of atherosclerosis—an up­
date. Ν Engl J Med 1986;314:488-500. 
123. Andrews HE, Bruckdorfer KR, Dunn RC, et al: Low-
density lipoproteins inhibit endothelium-dependent 
relaxation in rabbit aorta. Nature 1987;327:237-239. 
124. Bassenge E, Galle J: Suppression of EDRF-mediated va­
sodilatation by low density lipoproteins by two differ­
ent mechanisms. J Vase Biol Med 1989,1:77. 
125. Boulanger C, Biihler FR, Luscher TF: Low density lipo­
proteins impair the release of endothelium-derived re­
laxing factor from cultured porcine endothelial cells 
(abstr). Eur Heart J 1989;10:331. 
126. Grag UC, Hassid A: Nitric oxide-generating vasodila­
tors and 8-bromo-cyclic guanosine monophosphate in­
hibit mitogenesis and proliferation of cultured vascular 
smooth muscle cells. J Clin Invest 1989;83:1774-1777. 
127. Shimokawa H, Vanhoutte PM: Impaired endothelium-
dependent relaxation to aggregating platelets and re­
lated vasoactive substances in porcine coronary arteries 
in hypercholesterolemia and atherosclerosis. Circ Res 
1989;64:900-914. 
128. Bossaller C, Habib GB, Yamamoto H, et al: Impaired 
muscarinic endothelium-dependent relaxation and cy­
clic guanosine 5'-monophosphate formation in athero­
sclerotic human coronary artery and rabbit aorta. J Clin 
Invest 1987;79:170-174. 
129. Forstermann U, Mugge A, Alheid U, et al: Selective 
attenuation of endothelium-mediated vasodilation in 
atherosclerotic human coronary arteries. Circ Res 
1988;62:185-190. 
130. Verbeuren TJ, Jordaens FH, Zonnekeyn LL, et al: Effect 
of hypercholesteremia in vascular reactivity in the rab­
bit. I. Endothelium-dependent relaxations in isolated 
arteries of control and hypercholesteremic rabbits. Circ 
Res 1986;58:552-564. 
330 LUSCHER AJH-APRIL 1990-VOL 3, NO. 4 
131. Freiman PC, Mitchell GG, Heistad DD, et al: Athero­
sclerosis impairs endothelium-dependent vascular re­
laxation to acetylcholine and thrombin in primates. Circ 
Res 1986;58:783-789. 
132. Ludmer PL, Selwyn AP, Shook TL, et al: Paradoxical 
vasoconstriction induced by acetylcholine in athero­
sclerotic coronary arteries. Ν Engl J Med 1986; 
315:1046-1051 . 
133. Spokas EG, Folco G, Quilley J, et al: Endothelial mecha­
nism in the vascular action of hydralazine. Hyperten­
sion 1983;5(suppl I ) : 1 0 7 - l l l . 
134. Schultz P, Tolins J, Raij L: Effect of oral administration 
of antihypertensive agents on endothelium dependent 
and endothelium independent vascular relaxation 
(abstr). J Amer Col Cardiol 1989;13:83A. 
135. Laragh JH, Baer L, Brunner HR, et al: Renin, angioten­
sin and aldosterone system in pathogenesis and man­
agement of hypertensive vascular disease. Am J Med 
1972;52:633-652. 
136. Limas C, Westrum B, Limas CJ, et al: Effect of salt on the 
vascular lesions of spontaneously hypertensive rats. 
Hypertension 1980;2:477-489. 
137. Khaw K-T, Barrett-Connor E: Dietary potassium and 
stroke-associated mortality. Ν Engl J Med 1987; 
316:235-240 . 
138. Tobian L, Lange JM, Ulm KM, et al: Potassium prevents 
death from strokes in hypertensive rats without lower­
ing blood pressure. J Hypertens 1984;2(suppl 3 ) :363-
366. 
139. Tobian L, MacNeill D, Johnson MA, et al: Potassium 
protection against lesions of the renal tubules, arteries, 
and glomeruli and nephron loss in salt-loaded hyper­
tensive rats. Hypertension 1984;6(suppl I ) :170-176. 
140. Raij L, Luscher TF, Vanhoutte PM: High dietary potas­
sium augments endothelium-dependent relaxations in 
the Dahl rat. Hypertension 1988;12:562-567. 
141. Ballard-Barbash R, Callaway CW: Marine fish oils: Role 
in prevention of coronary artery disease. Mayo Clin 
Proc 1987;62:113-118. 
142. Weiner BH, Ockene IS, Levine PH, et al: Inhibition of 
atherosclerosis by cod-liver oil in a atherosclerotic 
swine model. Ν Engl J Med 1986;315:841-846. 
143. Shimokawa H, Vanhoutte PM: Dietary cod-liver oil im­
proves endothelium-dependent responses in hyper-
cholesterolemic and atherosclerotic porcine coronary 
arteries. Circulation 1988;78:1421-1430. 
144. Shimokawa I, Aarhus LL, Vanhoutte PM. Dietary ω3 
polyunsaturated fatty acids augment endothelium-de­
pendent relaxation to bradykinin in coronary microves-
sels of the pig. Br J Pharmacol 1988;95:1191-1196. 
145. Boulanger C, Schini VB, Vanhoutte PM: Effect of 
chronic exposure to eicosapentaenoic acid on the re­
lease of relaxing factor and the production of cyclic 
GMP by cultured endothelial cells (abstr). J Vase Med 
Biol 1989;1:79. 
146. Knapp HR, FitzGerald GT: The antihypertensive effect 
of fish-oil. Ν Engl J Med 1989;320:1837-1843. 
